Audience

HCP panel (US)

HCP (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.

10 insights·0 studies

What did the HCP panel say?

  1. #

    65.2%

    65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine — Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep

    base 198

  2. #

    66.7%

    Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. — Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit

    base 198

  3. #

    58.6%

    58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. — Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points

    base 169

  4. #

    73.2%

    73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore. — New indication news: 73% of US clinicians, mostly dermatologists, would ignore the manufacturer's email first, and none would read more than three promotional emails a month

    base 198

What has Brox published on hcp panel (us)?Newest first

What do people ask about hcp panel (us)?

What do physicians want from a medical science liaison that a sales rep cannot give them?
Real-world and subgroup evidence for patients like their own: 60.1% of US physicians and other prescribers on the Brox HCP panel name it as what they most want from a medical science liaison that a sales rep cannot give, and 65.2% rate a 20-minute liaison meeting at least moderately useful against 17.7% for a rep meeting (n=198, November 2026).Read the insight
Would a physician trust an AI summary of a new drug's trial data over the label or a rep?
Over the rep but not the label: 55.1% of US physicians and other prescribers on the Brox panel would rely on an AI summary of a new medicine's pivotal trial when every number links to the published paper, none would rely on one with no sources, and 66.2% would ignore the sales rep first against 24.2% the AI summary and 0% the FDA label (n=198, November 2026).Read the insight
What makes a doctor stop seeing pharma reps altogether?
Being asked too often, and their employer: 66.7% of US clinicians on the Brox HCP panel would decline a 10-minute pharma rep visit every two weeks against 39.4% monthly, and 24 of the 36 who no longer see reps name a practice or health system restriction (n=198, November 2026).Read the insight
What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?
58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).Read the insight
How do clinicians want to hear about a new indication for a medicine they already prescribe, and which channel actually changes what they prescribe?
When a medicine they already prescribe gains a new FDA-approved indication, 73.2% of US clinicians on the Brox panel would ignore the manufacturer's email about it first, and 71.7% would rather hear first from a colleague, a conference, or a journal (n=198, October 2026).Read the insight
What share of physicians discount pharmaceutical promotional content because AI was involved in writing it?
Only 2 of 173 US physicians on the Brox panel would discount pharmaceutical promotional content because AI was involved in writing it, while 63% say they begin discounting it when no expert has reviewed it (n=173, October 2026).Read the insight
How do physicians decide between a generic and a branded medicine when both are on formulary?
When a patient asks for the brand and their plan covers both versions, 88.9% of US clinicians on the Brox panel would prescribe the generic once the brand costs the patient $15 a month more (n=198, October 2026).Read the insight
What makes an oncologist adopt a newly approved first-line cancer therapy straight away, rather than wait for guidelines, payer coverage or peers?
14 of 18 US oncologists in the Brox HCP panel say prior authorization or coverage denials, not the trial data or the guideline listing, are what most often delay their first prescription of a newly approved first-line cancer regimen (n=18, October 2026).Read the insight
When an adult patient has ADHD alongside significant anxiety, what does a US physician do first, and what would change it?
Of the ten US physicians on the panel who manage adult ADHD with comorbid anxiety, none refers the patient straight out: six treat the anxiety first, and nine said evidence that one daily medicine improved both conditions would make them treat the ADHD themselves (September 2026).Read the insight
How do physicians feel about biosimilar substitution, and where do they push back?
Half of US physicians who manage biologics (50.0%, n=146, September 2026) are uncomfortable with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them, against 2.7% when they choose the switch themselves.Read the insight

Other audiences

How should you read these findings?

Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.

Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.

What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.

Ask this of your own customers: humans@brox.ai